[go: up one dir, main page]

ES2614481T3 - Composición para la administración de principios activos mediante dispositivos de implante - Google Patents

Composición para la administración de principios activos mediante dispositivos de implante Download PDF

Info

Publication number
ES2614481T3
ES2614481T3 ES11785091.7T ES11785091T ES2614481T3 ES 2614481 T3 ES2614481 T3 ES 2614481T3 ES 11785091 T ES11785091 T ES 11785091T ES 2614481 T3 ES2614481 T3 ES 2614481T3
Authority
ES
Spain
Prior art keywords
excipient
composition
administration
active ingredients
implant devices
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11785091.7T
Other languages
English (en)
Inventor
Maria Curcio
Ilaria Zambaldi
Daniela Gramaglia
Andrea Grignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CID SpA
Original Assignee
CID SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CID SpA filed Critical CID SpA
Application granted granted Critical
Publication of ES2614481T3 publication Critical patent/ES2614481T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/426—Immunomodulating agents, i.e. cytokines, interleukins, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43—Hormones, e.g. dexamethasone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Composición para la administración de por lo menos un principio activo en el sitio de implantación de un dispositivo de implante, incluyendo la composición: - dicho por lo menos un principio activo, y - por lo menos un primer excipiente combinado con dicho por lo menos un principio activo, siendo dicho por lo menos un primer excipiente seleccionado de entre ácidos grasos con una cadena saturada, lineal o ramificada, que incluye un número de átomos de carbono de entre 14 y 36, en la que dicha composición incluye además por lo menos un segundo excipiente diferente de dicho por lo menos primer excipiente y combinado con dicho por lo menos un principio activo, siendo dicho por lo menos segundo excipiente seleccionado de entre ácidos grasos con una cadena saturada, lineal o ramificada, que incluye un número de átomos de carbono de entre 14 y 36, en la que dicho por lo menos primer excipiente se selecciona de entre ácido esteárico y ácido behénico y en la que dicho por lo menos segundo excipiente se selecciona de entre ácido palmítico y ácido mirístico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11

Claims (1)

  1. imagen1
ES11785091.7T 2010-09-20 2011-09-19 Composición para la administración de principios activos mediante dispositivos de implante Active ES2614481T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITTO2010A000766A IT1402654B1 (it) 2010-09-20 2010-09-20 Composizione per il rilascio di principi attivi da dispositivi di impianto
ITTO20100766 2010-09-20
PCT/IB2011/054092 WO2012038881A1 (en) 2010-09-20 2011-09-19 Composition for active principles delivery by implant devices

Publications (1)

Publication Number Publication Date
ES2614481T3 true ES2614481T3 (es) 2017-05-31

Family

ID=43720863

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11785091.7T Active ES2614481T3 (es) 2010-09-20 2011-09-19 Composición para la administración de principios activos mediante dispositivos de implante

Country Status (6)

Country Link
US (1) US9011898B2 (es)
EP (1) EP2618859B1 (es)
CN (1) CN103118716B (es)
ES (1) ES2614481T3 (es)
IT (1) IT1402654B1 (es)
WO (1) WO2012038881A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523588A (ja) * 2013-05-06 2016-08-12 アボット カーディオヴァスキュラー システムズ インコーポレイテッド 治療剤配合物が充填されている中空ステント
DE102013110294B4 (de) 2013-09-18 2016-07-07 Innora Gmbh Limus-Depot-Formulierung auf Ballonkathetern
ITUA20162087A1 (it) * 2016-03-29 2017-09-29 Cid S P A Perfezionamenti negli stent per il rilascio di principi attivi
ITUA20162094A1 (it) * 2016-03-29 2017-09-29 Cid S P A Perfezionamenti negli stent per il rilascio di principi attivi
ITUA20162092A1 (it) * 2016-03-29 2017-09-29 Cid S P A Perfezionamenti negli stent per il rilascio di principi attivi
AU2017280351B2 (en) * 2016-06-24 2020-09-03 W. L. Gore & Associates, Inc. Drug coated balloons and techniques for increasing vascular permeability

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR012448A1 (es) 1997-04-18 2000-10-18 Ipsen Pharma Biotech Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada
US20030077310A1 (en) * 2001-10-22 2003-04-24 Chandrashekhar Pathak Stent coatings containing HMG-CoA reductase inhibitors
US7628807B2 (en) * 2004-11-04 2009-12-08 Boston Scientific Scimed, Inc. Stent for delivering a therapeutic agent having increased body tissue contact surface
JP2009511215A (ja) * 2005-10-15 2009-03-19 アトリウム メディカル コーポレーション 生体吸収性薬物担体コーティング用の疎水性架橋ゲル
ITTO20070356A1 (it) * 2007-05-21 2008-11-22 Sorin Biomedica Cardio Srl "composizione per il rilascio di principi attivi da dispositivi di impianto"

Also Published As

Publication number Publication date
EP2618859B1 (en) 2016-11-09
EP2618859A1 (en) 2013-07-31
US9011898B2 (en) 2015-04-21
ITTO20100766A1 (it) 2012-03-21
HK1185573A1 (zh) 2014-02-21
IT1402654B1 (it) 2013-09-13
CN103118716A (zh) 2013-05-22
US20130280315A1 (en) 2013-10-24
WO2012038881A1 (en) 2012-03-29
CN103118716B (zh) 2016-02-24

Similar Documents

Publication Publication Date Title
ES2614481T3 (es) Composición para la administración de principios activos mediante dispositivos de implante
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
ES2529725T3 (es) Combinaciones de principios activos nematicidas que comprenden fluopiram y Metarhizium
ES2613674T3 (es) Uso del organismo fúngico Pythium oligandrum
ES2539861T3 (es) Formulaciones en emulsión de clevidipina que contienen agentes antimicrobianos
ES2497494T3 (es) Método de tratamiento y prevención del hiperparatiroidismo secundario
ES2620742T3 (es) Formulaciones de principio activo que contienen 2-tiazol-4il-1H-benzoimidazol (tiabendazol o TBZ) para la fabricación de WPC
CR20170242A (es) Benzamidas sustituidas copn 1,3-tiazol-2-ilo
CL2015001981A1 (es) (divisional solicitud 1567-2013)combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
CR20110110A (es) Composicion farmaceutica
CL2012003573A1 (es) Combinaciones que comprenden un derivado de antranilamida y otro principio activo con propiedades insecticidas y acaricidas; composiciones agroquimicas que contienen; uso de dicha combinacion; procedimiento para combatir parasitos animales; y procedimiento para la preparacion de dicha composicion agroquimica.
CO6210778A2 (es) Agentes que contienen n-arilpirazol y carbonatos ciclicos alifaticos
NI201200189A (es) "composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona"
BRPI0922806B8 (pt) composição farmacêutica oral compreendendo bendamustina
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
CL2015002253A1 (es) Composiciones farmacéuticas para el tratamiento de la helicobacter pylori.
UA116886C2 (uk) Препаративна форма йодосульфурон-метилу натрієвої солі
RU2009128593A (ru) Средства борьбы с паразитами животных
CL2012003341A1 (es) Composicion farmaceutica de administracion oral que compende bendamustina o un ester, una sal o un solvato de la misma, y un excipiente que es un agente tensioactivo no ionico e hidrofilico; combinacion farmaceutica; y su uso para el tratamiento de leucemia linfocitica cronica y el mieloma multiple, entre otras enfermedades.
GT201300182A (es) Metodo para el tratamiento de una infeccion
CL2015002832A1 (es) Formulación farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa.
ES2563632T3 (es) Composición de micropartículas biocompatibles de ácido algínico para la liberación controlada de principios activos por vía intravenosa
AR082771A1 (es) Composicion de formulacion agroquimica
ES2510403T3 (es) Composición antioxidante, sinérgica